
|Videos|December 11, 2020
Management of high-risk NMIBC: Options for treatment expand
Author(s)Urology Times staff
“As urologists, we all need to start speaking in risk stratification criteria,” says Katie Murray, DO.
Advertisement
In this video, Katie Murray, DO, shares her takeaways from a discussion at the 2020 Society of Urologic Oncology annual meeting titled, Optimizing Management of High Risk NMIBC – Case-Based Discussion, for which she served as a panelist. Murray is an assistant professor of surgery-urology at the University of Missouri, Columbia.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Cretostimogene Grenadenorepvec: Mechanism and Rationale
5












